Understand the source comparison
TB-4 Research Intermediate Strategies: Protocol Comparison
Dose Selection Single dose from literature (typically 5–10mg/kg) 4-point dose escalation: 0.5, 2, 5, 10mg/kg Intermediate approach required to map pathway-specific thresholds—single dose provides outcome data but zero mechanistic insight Endpoint Measurement O
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dose Selection
- Single dose from literature (typically 5–10mg/kg)
- 4-point dose escalation: 0.5, 2, 5, 10mg/kg
- Intermediate approach required to map pathway-specific thresholds—single dose provides outcome data but zero mechanistic insight
- Endpoint Measurement
- One functional outcome at study termination
- Primary functional + 2 mechanistic endpoints at multiple timepoints
- Multi-endpoint approach separates correlation from causation and identifies which TB-4 pathway drives observed effect
- Reconstitution Method
- Full vial reconstituted, stored at 4°C, used across study duration
- Aliquoted into single-use doses, snap-frozen at −80°C, thawed immediately before use
- Aliquoting preserves >95% activity for 8–12 weeks; refrigerated storage loses 40%+ activity by day 21
- Sampling Schedule
- Single timepoint at study end (e.g., day 7 or day 28)
- Multiple timepoints matched to pathway kinetics: hours for actin, days for angiogenesis
- Pathway-specific timing captures peak activity windows—sampling too early or too late produces false negatives
- Controls
- Vehicle-only negative control
- Vehicle control + TB-4 dose ladder + pathway-specific inhibitor (e.g., cytochalasin D for actin, anti-VEGF for angiogenesis)
- Inhibitor controls definitively prove mechanism by blocking the pathway and abolishing the TB-4 effect